Stock Scorecard



Stock Summary for Repligen Corp (RGEN) - $138.90 as of 11/20/2024 8:38:57 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RGEN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RGEN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RGEN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RGEN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RGEN (47 out of 90)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0

Latest News for for RGEN

Company News for Nov 13, 2024 11/13/2024 9:21:00 AM
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View 11/12/2024 6:37:00 PM
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth - Repligen ( NASDAQ:RGEN ) 11/12/2024 6:19:00 PM
Repligen ( RGEN ) Q3 Earnings and Revenues Beat Estimates 11/12/2024 2:05:00 PM
Iovance Biotherapeutics ( IOVA ) Reports Q3 Loss, Tops Revenue Estimates 11/7/2024 10:45:00 PM
Repligen Corporation to Present at Upcoming Investor Conferences - Repligen ( NASDAQ:RGEN ) 11/5/2024 12:30:00 PM
Amgen ( AMGN ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release 10/23/2024 2:01:00 PM
Repligen ( RGEN ) Earnings Expected to Grow: What to Know Ahead of Q3 Release 10/22/2024 2:01:00 PM
Single-use Bioreactors Market Size is Set to Grow to USD 6.7 Billion by 2034 with a CAGR of 10.8% , Driven by Demand in Food and Industrial Biotechnology | Exclusive Report by Transparency Market Research Inc. 9/26/2024 11:30:00 PM
Repligen Opens Training & Innovation Center to Elevate Customer Experience - Repligen ( NASDAQ:RGEN ) 9/24/2024 11:30:00 AM

Financial Details for RGEN

Company Overview

Ticker RGEN
Company Name Repligen Corp
Country USA
Description Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 138.90
Price 4 Years Ago 191.63
Last Day Price Updated 11/20/2024 8:38:57 PM EST
Last Day Volume 818,398
Average Daily Volume 646,277
52-Week High 211.13
52-Week Low 113.50
Last Price to 52 Week Low 22.38%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE 101.51
Free Cash Flow Ratio 9.92
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 10.44
Total Cash Per Share 14.00
Book Value Per Share Most Recent Quarter 35.53
Price to Book Ratio 15.83
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 10.80
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 56,006,000
Market Capitalization 7,779,233,400
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.68%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -83.00%
Annual Earnings Growth -77.64%
Reported EPS 12 Trailing Months -0.30
Reported EPS Past Year 0.60
Reported EPS Prior Year 1.73
Net Income Twelve Trailing Months -18,335,000
Net Income Past Year 41,577,000
Net Income Prior Year 185,959,000
Quarterly Revenue Growth YOY 9.70%
5-Year Revenue Growth 27.21%
Operating Margin Twelve Trailing Months -0.02

Balance Sheet

Total Cash Most Recent Quarter 783,964,000
Total Cash Past Year 751,323,000
Total Cash Prior Year 623,757,000
Net Cash Position Most Recent Quarter 262,357,000
Net Cash Position Past Year 171,728,000
Long Term Debt Past Year 579,595,000
Long Term Debt Prior Year 284,615,000
Total Debt Most Recent Quarter 521,607,000
Equity to Debt Ratio Past Year 0.77
Equity to Debt Ratio Most Recent Quarter 0.79
Total Stockholder Equity Past Year 1,964,845,000
Total Stockholder Equity Prior Year 1,910,700,000
Total Stockholder Equity Most Recent Quarter 2,016,686,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 107,209,000
Free Cash Flow Per Share Twelve Trailing Months 1.91
Free Cash Flow Past Year 74,930,000
Free Cash Flow Prior Year 38,737,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.16
MACD Signal 0.04
20-Day Bollinger Lower Band 120.50
20-Day Bollinger Middle Band 141.92
20-Day Bollinger Upper Band 163.33
Beta 0.96
RSI 57.18
50-Day SMA 160.87
150-Day SMA 170.05
200-Day SMA 185.78

System

Modified 11/19/2024 11:30:09 AM EST